Cervical cancer
Cervical cancer
复制标题
DOI：
10.1097/01.aog.0000215986.48590.79
复制
发表时间：
2006-05-01
影响因子：
7.2
通讯作者：
Moore, David H.
中科院分区：
文献类型：
--
作者：
Moore, David H.
在世界范围内，宫颈癌是女性第二大常见恶性肿瘤，也是发病和死亡的主要原因。直到最近，随着筛查计划的出现和实施，降低宫颈癌死亡率方面取得了最大进展。宫颈癌的诊断和治疗也取得了许多重要进展。这篇综述文章将重点介绍诊断和分期注意事项，重点是更新的成像方式以及它们如何增强已批准的FIGO临床分期。将讨论早期疾病、局部晚期（IIB-IVA 期）疾病和转移性宫颈癌患者的治疗替代方案。只要有可能，这些讨论将通过相关临床试验和当前争议的概述来展开。
Worldwide, cervical cancer is the second most common malignancy in women and a major cause of morbidity and mortality. Until recently, the greatest strides in reducing cervical cancer mortality have occurred with the advent and implementation of screening programs. Many important advances have also taken place in the diagnosis and treatment of cervical cancer. This review article will highlight diagnostic and staging considerations with an emphasis on newer imaging modalities and how they might augment approved FIGO clinical staging. Management alternatives for patients with early-stage disease, locally advanced (stage IIB-IVA) disease, and metastatic cervical cancer will be discussed. Whenever possible, these discussions will unfold through an overview of pertinent clinical trials and current controversies.